Considering that most side effects can be mitigated via a lower dosage of drug administration, we thus propose that rational-based combination therapies involving HSP90 inhibitors may be more efficacious for cancer treatments that target oncogenic signaling pathways in parallel with reduced doses (Table 3). The gene discussed is HSP90AA1; the disease is cancer.